Phase III persevERA study of giredestrant combination in ER-positive advanced breast cancer does not meet primary objective

Durvalumab + enfortumab improves survival in patients with MIBC, VOLGA phase III trial finds

Combining immunotherapy with a targeted cancer drug before surgery, followed by immunotherapy, reduces the risk of death by 42% in in patients with muscle-invasive bladder cancer unable to receive standard chemotherapy, according to the phase III VOLGA clinical trial.

November 13, 2026

Vol.52 No.42

Clinical Roundup

Roginolisib regimens revert immune suppression in immunotherapy-resistant NSCLC, phase I/II study finds

Roginolisib-containing regimens were tolerable, reduced immunosuppressive activated regulatory T cells, and expanded stem-like CD8+ T cells, according to data from the phase I/II of PULMO-01.

November 13, 2026

Vol.52 No.42

Clinical Roundup

Pasritamig-based immunotherapy regimen shows 73% PSA response rate in advanced prostate cancer in phase I study

At the recommended regimen, 73% of patients receiving a pasritamig and JNJ-9401 combination, two bispecific antibodies designed to work together to drive the body’s immune response against advanced prostate cancer, achieved reductions of at least 50% in prostate-specific antigen, according to the results of a first-in-human phase I study.

November 13, 2026

Vol.52 No.42

Clinical Roundup

Two “forever chemicals” are associated with higher risk of aggressive breast cancer, NIH analysis finds

Women with higher blood levels of two common per- and polyfluoroalkyl substances, also familiarly known as PFAS, were more likely to develop estrogen receptor-negative, or ER-negative, breast cancer, according to a study by NIH.

November 13, 2026

Vol.52 No.42

Community sites have the patients to boost trial enrollment—but not the infrastructure

I have spent over 20 years running a tumor imaging metrics core at an academic cancer center. In that time, I have watched clinical trial enrollment concentrate at a relatively small number of flagship academic institutions. Unfortunately, trials do not propagate well to the community sites where most patients prefer to receive care. The explanations usually offered for why this happens have never fully accounted for what I observed.

Tarlatamab + durvalumab extends survival for patients with aggressive small cell lung cancer, phase III trial finds

In patients with extensive-stage small cell lung cancer, tarlatamab, a bispecific T-cell engager, plus durvalumab as first-line maintenance therapy extended median overall survival by more than eight months, more than tripled progression-free survival, and reduced the risk of death by 58% compared to durvalumab alone, according to the results of the phase III open-label, multicenter, randomized DeLLphi-305 study.

November 06, 2026

Vol.52 No.41

Phase III persevERA study of giredestrant combination in ER-positive advanced breast cancer does not meet primary objective

YOU MAY BE INTERESTED IN

Durvalumab + enfortumab improves survival in patients with MIBC, VOLGA phase III trial finds

Roginolisib regimens revert immune suppression in immunotherapy-resistant NSCLC, phase I/II study finds

Pasritamig-based immunotherapy regimen shows 73% PSA response rate in advanced prostate cancer in phase I study

Two “forever chemicals” are associated with higher risk of aggressive breast cancer, NIH analysis finds

Community sites have the patients to boost trial enrollment—but not the infrastructure

Tarlatamab + durvalumab extends survival for patients with aggressive small cell lung cancer, phase III trial finds

Renew today!

Subscriber content

Never miss an issue!

Login